Patient experience with darifenacin results of a short-term community-based survey in managing overactive bladder

Current Medical Research and Opinion

Volumn 27, Issue 2, 2011, Pages 431-437

  Green, Lonny ^a   Kerney, Donna ^b  

^a Virginia Women's Center   (United States)

^b InfoMedics Inc   (United States)

Author keywords

Clinical practice; Darifenacin; OAB; Overactive bladder

Indexed keywords

DARIFENACIN;

ADULT; AGED; ARTICLE; COMMUNITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIMARY MEDICAL CARE; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; URGE INCONTINENCE;

AGED; BENZOFURANS; DATA COLLECTION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PYRROLIDINES; RESIDENCE CHARACTERISTICS; SELF REPORT; TIME FACTORS; URINARY BLADDER, OVERACTIVE;

EID: 78651389296     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.541432     Document Type: Article

References (35)

1. Stewart W, Herzog R, Wein A, et al. Prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn 2001;20:406-8
2. Onukwugha E, Zuckerman IH, McNally D, et al. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care 2009;15:S90-S97
3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002;187:116-26
4. Garnett S, Swithinbank L, Ellis-Jones J, et al. The long-term natural history of overactive bladder symptoms due to idiopathic detrusor overactivity in women. BJU Int 2009;104:948-53
5. Gray M. Incontinence-related skin damage: essential knowledge. Ostomy Wound Manage 2007;53:28-32
6. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
7. Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures. J Am Geriatr Soc 2000;48:721-5
8. Coyne KS, Zhou Z, Bhattacharyya SK, et al. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 2003;92:948-54
9. Ricci JA, Baggish JS, Hunt TL, et al. Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther 2001;23:1245-59
10. Nicolson P, Kopp Z, Chapple CR, et al. It's just the worry about not being able to control it! A qualitative study of living with overactive bladder. Br J Health Psychol 2008;13:343-59
11. Helfand BT, Evans RM, McVary KT. A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients. Eur Urol 2010;57:586-91
12. Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology 2010;75:526-32
13. Reeves P, Irwin D, Kelleher C, et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006;50:1050-7
14. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53
15. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
16. 3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005;95:993-1001
17. 3-selective receptor antagonist. BJU Int 2005;95:580-6
18. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006;98:1025-32
19. Donovan A, Bosch R, Gotoh M, et al. Symptom and quality of life assessment. In: Abrams P, Cardozo L, Khoury S, Wein A (eds). Incontinence. Book 1. Basics and evaluation. International Continence Society, 2005
20. Abrams P, Huels J, Kelleher C. Clinical relevance of quality of life data with darifenacin in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2005;16:S101
21. Weaver M, Patrick DL, Markson LE, et al. Issues in the measurement of satisfaction with treatment. Am J Manag Care 1997;3:579-94
22. McCracken LM, Klock PA, Mingay DJ, et al. Assessment of satisfaction with treatment for chronic pain. J Pain Symptom Manage 1997;14:292-9
23. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of trans-dermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580-6
24. Schabert VF, Bavendam T, Goldberg EL, et al. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care 2009;15:S118-S122
25. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40
26. Zinner N, Kobashi K, Koochaki P, et al. Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument. Neurourol Urodyn 2010;in press. doi: 10.1002/nau.20890
27. Cohen SJ, Robinson D, Dugan E, et al. Communication between older adults and their physicians about urinary incontinence. J Gerontol A Biol Sci Med Sci 1999;54:M34-M37
28. Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010;105:1276-82
29. Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin 2007;23:65-76
30. Marschall-Kehrel D, Roberts RG, Brubaker L. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology 2006;68:29-37
31. Cardozo L, Hessdorfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008;102:1120-7
32. Rudy D, Cline K, Harris R, et al. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int 2006;97:540-6
33. Sussman DO, Kraus SR, Carlsson M, et al. Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin 2007;23:777-81
34. Khullar V, Foote J, Larson-Peters A, et al. Darifenacin effectively relieved overactive bladder symptoms as early as 6-8 days of initiating treatment. ICS/IUGA Toronto, Canada, August 23-27, 2010;Abstract 620
35. FDA Report. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2006. Available at: http://www.fda.gov/ohrms/dockets/dockets/06d0044/06D-0044-EC30-Attach-1.pdf [Last accessed: 21 July 2010]